PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Clinical Trials
5.0k
Trial Phases
6 Phases
Drug Approvals
17
Drug Approvals
Rimegepant Sulfate Orally Disintegrating Tablets
- Product Name
- 乐泰可
- Approval Number
- 国药准字HJ20240004
- Approval Date
- Jan 23, 2024
Ritlecitinib Tosylate Capsules
- Product Name
- 乐复诺
- Approval Number
- 国药准字HJ20230118
- Approval Date
- Oct 18, 2023
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (3896 trials with phase data)• Click on a phase to view related trials
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC)Hormone Sensitive Prostate CancerProstate CancerCancer of the Prostate
- Interventions
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1000
- Registration Number
- NCT07028853
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
🇺🇸Arizona Urology Specialists, PLLC, Tucson, Arizona, United States
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
- Conditions
- Severe Alopecia Areata
- Interventions
- Drug: Ritlecitinib higher doseDrug: Ritlecitinib lower dose
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 140
- Registration Number
- NCT07029828
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
- Conditions
- Severe Alopecia Areata
- Interventions
- Drug: Ritlecitinib higher doseDrug: Ritlecitinib lower doseDrug: Placebo
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 225
- Registration Number
- NCT07029711
A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT07023081
- Locations
- 🇨🇳
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, China
🇨🇳Wuming District Center for Disease Control and Prevention, Chengxiang, Nanning, China
A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults
- Conditions
- Pneumococcal Disease
- Interventions
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT07019909
- Locations
- 🇨🇳
Zhejiang provincial center for disease control and prevention, Hangzhou, Zhejiang, China
🇨🇳Kaihua County Center For Disease Prevention and Control, Kaihua, Zhejiang, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 635
- Next
News
ViiV Healthcare Presents Real-World Data on Long-Acting HIV Treatments at IAS 2025
ViiV Healthcare presented extensive real-world data at IAS 2025 demonstrating the effectiveness, safety, and tolerability of its long-acting injectable HIV treatments, including cabotegravir + rilpivirine LA for treatment and cabotegravir LA for prevention.
Taiho's Pizuglanstat Fails to Meet Primary Endpoint in Phase III Duchenne Muscular Dystrophy Trial
Taiho Pharmaceutical's pizuglanstat (TAS-205) failed to demonstrate significant improvement in time to rise from floor compared to placebo in the Phase III REACH-DMD study.
Ascentage Pharma Strengthens Leadership Team with New CFO and Senior VP Appointments
Ascentage Pharma appointed Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance to support the company's global expansion strategy.
CDSCO Expert Committee Accepts Pfizer's Phase III Data for Abrocitinib in Atopic Dermatitis
India's CDSCO expert committee has accepted Pfizer's Phase III clinical trial data for abrocitinib, a selective JAK1 inhibitor for moderate-to-severe atopic dermatitis treatment.
Everest Medicines Advances AI-Powered mRNA Platform with Cancer Vaccine Breakthroughs
Everest Medicines unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day, showcasing a fully integrated system spanning antigen design to manufacturing.
iQure Pharma Appoints Former UCB Chief Medical Officer Iris Loew-Friedrich as Clinical and R&D Advisor
iQure Pharma, a clinical-stage biotech company developing treatments for CNS disorders through glutamate balance restoration, has appointed Prof. Dr. Iris Loew-Friedrich as Clinical and R&D Advisor.
House Republicans Subpoena Former Pfizer Executive Over Alleged COVID-19 Vaccine Trial Delays
House Judiciary Committee subpoenaed former Pfizer executive Dr. Philip Dormitzer over allegations that senior Pfizer executives deliberately slowed COVID-19 vaccine clinical testing before the 2020 election.
Pfizer Terminates Phase II CD47 Trial in Blood Cancer Due to Recruitment Challenges
Pfizer has terminated a Phase II trial of maplirpacept in diffuse large B-cell lymphoma after enrolling only six patients since August 2023 due to recruitment difficulties.
Avacta Strengthens Leadership Team with Appointment of Chief Medical Officer and Business Development Advisor
Avacta Group plc has appointed David Liebowitz, M.D., Ph.D. as Chief Medical Officer to lead clinical strategy and execution for its targeted cancer therapy pipeline.
Artelo Biosciences Stock Surges Over 130% Following Positive Preclinical Depression Data and First-in-Human Pain Trial Results
Artelo Biosciences shares soared over 130% after reporting positive preclinical data for ART12.11 in stress-induced depression, showing efficacy comparable to Pfizer's Zoloft.